Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment
V.B.C. Biemans, C.J. van der Woude, G. Dijkstra, A.E. van der Meulen-de Jong, M. Lowenberg, N.K. de Boer, B. Oldenburg, N. Srivastava, J.M. Jansen, A.G.L. Bodelier, R.L. West, A.C. de Vries, J.J.L. Haans, D. de Jong, F. Hoentjen, M.J. Pierik*, Dutch Initiative Crohn and Colitis
Research output: Contribution to journal › Article › Academic › peer-review
Fingerprint
Dive into the research topics of 'Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment'. Together they form a unique fingerprint.